Shenyang Sunshine Pharmaceutical

Subsidiary of 3SBio Inc. (1530)

Assets

(5 total)
5Total Assets
0Approved
3Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
FLT3Small molecule
Acute Myeloid Leukemia
Phase 3
Erythropoietin receptor (EPO-R)Biologic (subtype unspecified)
Chronic Kidney Disease
Phase 3
PD-1 + VEGFMultispecific antibody
Non-Small Cell Lung CancerColorectal CancerEndometrial Cancer
Phase 2
PD-1 and PD-L1Multispecific antibody
Non-Small Cell Lung Cancer
Phase 2
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SSGJ-706Phase 2Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2026-12 · NCT07233850 · CT.gov ↗
What to watch
2027 (7)
October 2027 (1)
PF-08634404Phase 1/2Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms …
Est. primary completion 2027-10-18 · NCT07227012 · CT.gov ↗
What to watch
November 2027 (3)
SSGJ-706Phase 2Non Small Cell Lung Cancer
Est. primary completion 2027-11 · NCT07874984 · CT.gov ↗
What to watch
PF-08634404Phase 1/2Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma …
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
Clifutinib BesylatePhase 3Leukemia, Acute Myeloid (AML)
Est. primary completion 2027-11-30 · NCT05586074 · CT.gov ↗
What to watch
December 2027 (3)
Loncipoetin alfa (NuPIAO)Phase 2Chemotherapy-induced Anemia, Non-myeloid Malignancies
Est. primary completion 2027-12-01 · NCT06854276 · CT.gov ↗
What to watch
PF-08634404Phase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
Clifutinib BesylatePhase 1/2Acute Myeloid Leukemia, Adult
Est. primary completion 2027-12-31 · NCT05133882 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
PF-08634404Phase 2Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung …
Est. primary completion 2028-03-24 · NCT07476287 · CT.gov ↗
What to watch
July 2028 (1)
PF-08634404Phase 2Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease …
Est. primary completion 2028-07-29 · NCT07489066 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
PF-08634404Phase 3Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) …
Est. primary completion 2029-02-27 · NCT07222566 · CT.gov ↗
What to watch
March 2029 (1)
PF-08634404Phase 1/2Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Est. primary completion 2029-03-08 · NCT07227298 · CT.gov ↗
What to watch
June 2029 (1)
PF-08634404Phase 3Endometrial Neoplasms, Endometrial Cancer
Est. primary completion 2029-06-01 · NCT07578649 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
PF-08634404Phase 3Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases …
Est. primary completion 2030-02-23 · NCT07222800 · CT.gov ↗
What to watch
June 2030 (1)
PF-08634404Phase 2/3Small Cell Lung Cancer (SCLC)
Est. primary completion 2030-06-14 · NCT07226999 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
PF-08634404Phase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer …
Est. primary completion 2031-07-22 · NCT07392892 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2024Topline resultrESPSSS06 (rESP) Phase 3 (NCT05211167) completed in January 2024 and reached its pre-set primary endpoint
3SBio Inc. · Source ↗

Financial reports

No financial reports recorded.